Edgewise Therapeutics Inc Asset Resilience Ratio
Edgewise Therapeutics Inc asset resilience ratio. Edgewise Therapeutics Inc (EWTX) has an Asset Resilience Ratio of 89.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Edgewise Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Edgewise Therapeutics Inc (2019–2025)
Asset resilience ratio of Edgewise Therapeutics Inc from 2019 to 2025. This chart shows how Edgewise Therapeutics Inc's Asset Resilience Ratio has changed over time. Read EWTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Edgewise Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see EWTX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $466.35 Million | 89.94% |
| Total Liquid Assets | $466.35 Million | 89.94% |
Asset Resilience Insights
- Very High Liquidity: Edgewise Therapeutics Inc maintains exceptional liquid asset reserves at 89.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Edgewise Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Edgewise Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Edgewise Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Edgewise Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Edgewise Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 84.86% | $468.96 Million | $552.60 Million | -3.16pp |
| 2024-12-31 | 88.02% | $428.50 Million | $486.82 Million | +19.71pp |
| 2023-12-31 | 68.32% | $232.30 Million | $340.04 Million | -21.57pp |
| 2022-12-31 | 89.88% | $329.95 Million | $367.10 Million | -3.10pp |
| 2021-12-31 | 92.98% | $265.22 Million | $285.23 Million | +74.55pp |
| 2020-12-31 | 18.44% | $24.18 Million | $131.14 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $24.54 Million | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more